Reading BCAX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track BCAX free→Reading BCAX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track BCAX free→QuarterlyIQ Insights · BCAX
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
and in Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
and in Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Results of Operations and Financial Condition. On February 24, 2026, the Company disclosed in a preliminary prospectus supplement related to the Offering that its preliminary unaudited cash, cash equivalents and investments as of December 31, 2025 were approximately $414.8 million. The preliminary financial data included in this Report has been prepared by, and is the responsibility of the Company’s management. KPMG LLP, the Company’s independent registered public accounting firm, has not aud…
Entry into a Material Definitive Agreement. On February 24, 2026, Bicara Therapeutics Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC, TD Securities (USA) LLC and BofA Securities, Inc., as representatives (the “Representatives”) of the underwriters named therein (the “Underwriters”), pursuant to which the Company agreed to issue and sell an aggregate of (i) 7,175,000 shares (the “Firm Shares”) of its common stock, par va…
and in Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “ Exchange Act ”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
and in Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “ Exchange Act ”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
Entry into a Material Definitive Agreement. On June 2, 2025, Bicara Therapeutics Inc. (the “Company”) entered into a Sublease Agreement (the "Sublease) with J.W. Childs Associates, L.P, (the “Sublandlord”), effective upon receipt of the consent of Columbia Reit – 116 Huntington, LLC, received on June 4, 2025, pursuant to which the Company will lease approximately 9,682 square feet of additional office space as part of its corporate headquarters, located at 116 Huntington Avenue, Suite 703, Bo…
and in Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “ Exchange Act ”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
Results of Operations and Financial Condition. On March 27, 2025, Bicara Therapeutics, Inc (the " Company ") issued a press release announcing its financial results and business highlights for the fourth quarter of fiscal year 2024 ended December 31, 2024. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information set forth under
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.